tirzepatide cardiovascular outcomes trial results august 2025 event risk assessment: a pre-specified meta-analysis CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN
Description
Prescription medications have reviewed labeling, dosing instructions, adverse-event reporting, manufacturing oversight, and clinician supervision
However, these side effects were mild to moderate and usually resolved within a few days
Risk reduction requires a consistent verification sequence
1998;6(Suppl 2):51S-209S
The treatment can help raise the eyebrows and subtly reduce hooded eyelids, but it may not provide dramatic surgical results like blepharoplasty
Individualised dose adjustment or alternative treatment options may be considered where necessary
